TScan Therapeutics Announces Updates to its Board of Directors
TScan Therapeutics, Inc. (TCRX)
Company Research
Source: GlobeNewswire
Garry A. Nicholson, an experienced executive with regulatory and commercial expertise, joins the Board of Directors Timothy Barberich retires as Chair; Stephen Biggar, M.D., Ph.D. assumes the role of Chair WALTHAM, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced changes to its Board of Directors. Garry A. Nicholson has been appointed to the Company’s Board of Directors. In addition, Timothy Barberich has retired as a Member and Chair of the Board of Directors. Current board member Stephen Biggar, M.D., Ph.D., will assume the role of Chair of the Board of Directors. “We are pleased to welcome Garry to our Board of Directors. He has a breadth of experience in oncology development and commercialization spanning more than 35 years, including serving as pres
Show less
Read more
Impact Snapshot
Event Time:
TCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TCRX alerts
High impacting TScan Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TCRX
News
- TScan Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire
- Director of TScan Therapeutics Barbara Klencke Buys 18% More Shares [Yahoo! Finance]Yahoo! Finance
- TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.MarketBeat
- TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $10.00 price target on the stock.MarketBeat
- TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $11.00 price target on the stock.MarketBeat
TCRX
Earnings
- 8/12/24 - Beat
TCRX
Sec Filings
- 9/24/24 - Form 4
- 8/27/24 - Form 4
- 8/27/24 - Form 4
- TCRX's page on the SEC website